Emerging drugs for autonomic dysfunction in Parkinson’s disease

Santiago Perez-Lloret†, María Verónica Rey, Anne Pavy-Le Traon & Olivier Rascol
†Faculty of Medicine, Department of Clinical Pharmacology, Toulouse, France

Introduction: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment.

Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered.

Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments.

Keywords: Botulinum toxin, clinical trials design, constipation, domperidone, droxidopa, erectile dysfunction, fipamezole, fludrocortisone, incontinence, lubiprostone, macrogol, muscarinic antagonists, non-motor symptoms, orthostatic hypotension, Parkinson’s disease, probiotics, sexual dysfunction, sialorrhea, solifenacin, urinary dysfunction

Expert Opin. Emerging Drugs (2013) 18(1):39-53

1. Background

Autonomic disturbances such as orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction or gastrointestinal motility disorders are frequent in Parkinson’s disease (PD) [1,2]. They can impair patient’s quality of life, worsen the burden of their caregivers, cause hospitalization and institutionalization and increase the cost of care of patients with PD by four times [1]. Their management and treatment have been recognized by the UK National Institute for Clinical Excellence as unmet needs in PD [3]. In this section, the authors will review prevalence and clinical characteristics of autonomic disorders in PD. Their physiopathology and prognosis will be discussed in other sections of this review article.

The OH affects 20 – 65% of patients with PD [4,5] and can be defined as a sustained reduction of systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of 10 mm Hg within 3 min of standing or head-up tilt to at least 60° on a tilt table [6]. Symptoms include generalized weakness, lightheadedness, dizziness or syncope in the worst cases [7].
Sialorrhea affects approximately 70–75% of patients [8,9]. In severe cases where drooling is evident, patients are forced to constantly use a handkerchief and clothes or shoes may be wet or stained. In less evident cases, only mouth corners may be wet or stained. Disturbed eating or speaking may also be observed in connection with sialorrhea.

Impaired sexual function in PD occurs in both men and women [2]. Erectile dysfunction (ED) and sexual dissatisfaction affects more than 60% of men [10]. Several studies have demonstrated that erectile problems are nearly twice as frequent in men with PD than in controls [11]. ED greatly affects PD patients’ quality of life and can take a serious psychological toll [12].

Several urinary dysfunctions are commonly observed in PD [1] and may affect up to 40% of patients [2]. The most common urinary problem in PD, involving 45–100% of individuals with urinary symptoms, is overactive bladder contraction, which produces urinary frequency, urgency, nocturia and incontinence.

Reduced gastrointestinal motility resulting in constipation is also a very common symptom of PD, affecting up to 80% of patients [2]. Constipation frequently precedes the diagnosis of PD.

2. Medical need

Levodopa non-responsive non-motor symptoms, including autonomic dysfunction, are frequently the most disabling feature of PD, as shown in prospective studies. For example, a survey of 163 consecutive symptomatic patients showed that difficulties with balance, sleep disturbance, memory failure or confusional episodes and dribbling of saliva were rated as the most disabling symptoms [1]. A recent study in 462 PD patients showed that depression, anxiety and non-motor symptoms were independent factors influencing quality of life in PD [13].

Comorbidities can also be found in connection with non-motor symptoms. For example, OH does not only cause significant morbidity and mortality, mainly from the sequelae of falls, but is also an independent risk factor for morbidity and mortality from heart disease, stroke and cardiovascular and all-cause mortality [14].

Sialorrhea may give rise to embarrassment, isolation and worsening of depressive symptoms [15]. Saliva that remains pooled in the mouth may become an aspiration source, and result in choking and pneumonia [16].

Urinary incontinence may also cause increased morbidity in PD. Moisture lesions or incontinence-associated dermatitis are painful and distressing consequences of prolonged exposure to urine [17]. They may adversely affect patients’ physical and psychological well-being, so minimizing damage is of vital importance.

Gastrointestinal hypomobility may reduce the absorption of levodopa. Indeed, the rate and extent of levodopa absorption of standard levodopa tablets is affected by food and other gastric factors that modulate gastric emptying including gastric pH, intestinal transit time and digestive enzymes [18]. Anecdotal evidence suggests that in extreme cases, constipation might trigger worsening of PD symptoms or motor fluctuations and occurrence of the malignant syndrome was observed after fecal impaction in a subject previously affected by severe constipation [19].

3. Existing treatments

Non-motor symptoms are frequently overlooked by neurologists [1]. Even though interest in such symptoms have greatly increased in the last years, treatments are still scarce for the majority of the conditions, as concluded by both the American Academy of Neurology [20] and the Movement Disorders Society [21] in their evidence-based medicine reviews. In this section, the authors will review drugs with documented efficacy for the treatment of autonomic dysfunction in PD and in other population of patients. Data are summarized in Table 1.

3.1 Orthostatic hypotension

Identification of the mechanism of OH (disease, drug or other causes) is the first step in the treatment, followed by non-pharmacological measures. In a recent cross-sectional study, it has been shown that exposure to diuretics, amantadine and polypharmacy (i.e., intake of more than five drugs) was more frequent in PD patients with OH [22]. Exposure to levodopa, dopamine agonists, α-adrenergic blockers used for prostatic hyperplasia, clonidine antihypertensives or many antidepressants can also produce or aggravate OH [23,24]. Therefore, the first therapeutic maneuver is to reconsider treatment with agents known to induce or aggravate hypotension [24]. Patients should also be advised to avoid precipitating factors such as sudden postural change, large meals, hot baths, alcohol and vasodilating medications [25]. Other non-pharmacological methods for treating OH include liberal addition of salt to the diet, exercise, compression stockings or physical maneuvers that help to raise blood pressure by increasing venous return and increasing peripheral resistance. A recent systematic review demonstrated that several common treatments for OH have been examined only in low-quality randomized, placebo-controlled trials [26]. This includes non-pharmacological measures as well as drugs such as midodrine or fludrocortisone, which are the first-line drugs [24]. Similarly, the Movement Disorders Society Evidence-Based Medicine (MDS-EBM) review did not identify any drug meeting its definition for being ‘clinically useful’ [21].

3.2 Sialorrhea

Treatment should begin by withdrawal of sialorrhea-inducing drug agents, such as cholinesterase inhibitors, clozapine or quetiapine [15]. The MDS-EBM review identified Botulinum toxin-A or -B (BTX-A or B, respectively), an acetylcholine release inhibitor, as ‘clinically useful’ and glycopyrrolate, a
peripheral-acting muscarinic receptor antagonist as ‘possibly useful’ for sialorrhea in PD [21]. The authors will review evidence about efficacy and safety of these drugs.

3.2.1 Botulinum toxin

Lagalla et al. conducted a double-blind, randomized, placebo-controlled trial on BTX-A [27]. Subjects received 50 units of BTX-A or matching placebo in each parotid gland. Sixteen patients were randomly assigned to each treatment arm. Patients under BTX-A showed a 40% reduction of visual analog scale (VAS) scores and a 50% reduction of buccal saliva contents, which were not observed in the placebo group (BTX-placebo difference p < 0.001). One patient complained about transient swallowing difficulties. No other adverse events were reported.

Ondo et al. conducted a double-blind, randomized, placebo-controlled study aiming to assess the efficacy and safety of intraglandular BTX-B injections [28]. Eight patients were randomly assigned to each treatment arm. Patients under BTX-A showed a 40% reduction of visual analog scale (VAS) scores and a 50% reduction of buccal saliva contents, which were not observed in the placebo group (BTX-placebo difference p < 0.001). One patient complained about transient swallowing difficulties. No other adverse events were reported.

3.2.2 Glycopyrrolate

Glycopyrrolate 1 mg three times per day were compared with placebo in 23 patients with PD [30]. Nine patients (39.1%) with glycopyrrolate had a clinically relevant improvement of at least 30% versus 1 patient (4.3%) with placebo (p < 0.021). There were no significant differences in adverse events between glycopyrrolate and placebo treatment.

3.3 Sexual dysfunction

Patient counseling [31] and re-evaluation of drug treatments potentially causing sexual dysfunction are the first step toward successful treatment [7]. Rigidity and bradykinesia contribute to general deterioration in sexual functioning [31]. Aging, depression, fatigue, sleep disorders, reduced testosterone secretion can also be important contributing factors [32]. Some drugs, such as antihypertensives or antidepressants can also cause or aggravate ED [33], and thus patients’ pharmacotherapy should be re-evaluated. Nonetheless, drug treatment often becomes necessary, based essentially on phosphodiesterase type 5 inhibitors, including sildenafil, tadalafil and vardenafil [34]. Treatment options for patients who do not respond to these drugs or for whom they are contraindicated include intracavernous injections, intraurethral alprostadil, vacuum constriction devices or implantation of a penile prosthesis.

Table 1. Efficacy and safety in PD of drugs used for the treatment of autonomic dysfunction in other population of patients.

| Drug                          | Action mechanism                      | Proved efficacy in PD | Potential safety issues                  |
|-------------------------------|---------------------------------------|-----------------------|------------------------------------------|
| OH                            | Increase venous blood flow            | No                    | None                                     |
| Non-pharmacological measures  | α1-Receptor agonist                   | No                    | Supine hypertension                       |
| Midodrine                     | Increase blood volume                 | No                    | Supine hypertension                       |
| Fludrocortisone               |                                       |                       |                                          |
| Sialorrhea                    | Inhibition of acetylcholine release   | Yes                   | Dysphagia                                |
| BTX-A or -B                   | Muscarinic antagonists                | Yes (glycopyrrolate)  | Memory loss and hallucinations            |
| Atropine, scopolamine,        |                                       |                       |                                          |
| glycopyrrolate, tropicarnide, |                                       |                       |                                          |
| Sexual dysfunction            |                                       |                       |                                          |
| Sildenafil                    | Phosphodiesterase-5 inhibitor         | No                    | None                                     |
| Stenodermine, tolterodine,    | Muscarinic antagonists                | No                    | Memory loss, hallucinations               |
| solifenacin                   |                                       |                       |                                          |
| BTX                           | Inhibition of acetylcholine release   | No                    | Post-void residue                         |
| Lactulose, macrogol, bisacodyl| Osmotic or secretive laxatives        | Yes (macrogol)         | Diarrhea                                  |
| sodium picosulfate            |                                       |                       |                                          |
| Mosapride, prucalopride       | 5-HT4 receptors agonist               | No                    | Diarrhea, cardiac arrhythmias             |
| Lubiprostone                  | Activator of intestinal chloride      | No                    | Diarrhea                                  |
| receptors                     |                                       |                       |                                          |
| Linaclootide                  | Guanylate cyclase 2C agonist          | No                    | Diarrhea                                  |

BTX: Botulinum toxin; OH: orthostatic hypotension.
Nevertheless, this is based on empirical approach, and the MDS-EBM review concluded that there were no drugs with documented efficacy for treatment of ED in PD [21].

3.4 Urinary dysfunction

Its treatment should begin by considering external causes such as prostate hypertrophy or cancer. Drug treatment may be considered afterward. A recent meta-analysis compared the efficacy of muscarinic receptor antagonists for the treatment of urgency urinary incontinence associated with bladder overactivity in women [35]. Continence was restored in 130 per 1000 women treated with fesoterodine (95% confidence interval (CI) 58 – 202), 85 with tolterodine (95% CI 40 – 129), 114 with oxybutynin (95% CI 64 – 163), 107 with solifenacin (95% CI 58 – 156) and 114 with trospium. Rates of discontinuation were higher with oxybutynin as compared with other drugs. Many papers have reported on the clinical success of BTX-A as a method of management of various bladder dysfunctions [36]. Injection of BTX-A appears to have a positive therapeutic effect in multiple urological conditions inducing urinary incontinence, such as refractory idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. Nowadays, BTX-A has been approved by the Food and Drug Administration for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity in adults who have an inadequate response to or are intolerant to anticholinergics. Non-pharmacological measures such as tibial nerve stimulation may also be considered in these cases [37].

The MDS-EBM review found no drug with documented efficacy for treatment of urinary dysfunction in PD [21].

3.5 Constipation

Changes in the diet and physical activity are the first treatment measures to be taken. Increased fluid and fiber intake should be encouraged, adding fiber supplements and stool softeners if necessary. Tricyclic antidepressants, loperamide, codeine phosphate, opioids, antimuscarinics and some antiparkinsonian drugs are frequent causes for severe constipation [38], thus warranting evaluation of patients drug treatment before taking further measures. Then, osmotic laxatives may be employed as a second option. Drug treatments should be considered as the last option.

A recent meta-analysis pooled data from placebo-controlled trials of laxatives or pharmacological therapies in adult patients with chronic idiopathic constipation [39]. Laxatives (relative risk (RR) = 0.52; 95% CI 0.46 – 0.60), prucalopride (RR = 0.82; 95% CI 0.76 – 0.88), lubiprostone (RR = 0.67; 95% CI 0.56 – 0.80) and linaclotide (RR = 0.84; 95% CI 0.80 – 0.87) were all superior to placebo in terms of a reduction in risk of failure with therapy. Laxatives included osmotic agents such as lactulose or polyethylene glycol (i.e., macrocol) and stimulants such as bisacodyl or sodium picosulfate, with similar results.

Mean number of stools per week was significantly higher with laxatives compared with placebo (weighted mean difference in number of stools per week = 2.55; 95% CI 1.53 – 3.57). Diarrhea was more frequent with all assessed drugs. Probiotics have been suggested to have favorable effects on gastrointestinal function including suppressing growth of pathogenic bacteria, blocking epithelial attachment by pathogens, enhancing mucosal function and modulating host immune response [40]. In a randomized, placebo-controlled study, a yogurt containing a mixture of Bifidobacterium animalis and prebiotic fructooligosaccharide administered twice a day for 2 weeks produced a 22% increase in the number of bowel movements per week and a slight increase in stool quality as assessed by the Bristol Stool Questionnaire when compared with placebo [40]. There is insufficient evidence to propose the utilization of other agents such as trimetubin, erythromycin or domperidone [41]. Tegaserod has been found to be effective, but due to safety issues it was withdrawn from the market [41].

3.5.1 Macrocol

The MDS-EBM taskforce considered macrocol, an osmotic agent, as a ‘possibly useful’ treatment for constipation in PD [21]. Zangaglia et al. studied the efficacy of an isosmotic 7.3 g macrocol electrolyte solution for the treatment of constipation in PD in a double-blind, randomized, placebo-controlled trial [42]. Fifty-seven patients were included in this study. Responders rate were higher in the macrocol group as compared with the placebo (80 vs 30%, p < 0.001). A higher rate of withdrawals was seen in the macrocol group compared with placebo.

4. Market review

General population estimates of incidence for PD range from 1.5 to 2.6 per 100,000 person-years [43,44]. Worldwide estimates of PD are projected to increase to 8.67 million by 2030 [45]. Prevalence of OH, sialorrhea, sexual dysfunction, urinary dysfunction or constipation, ranges from 20 – 65, 70 – 75, 60, 40 or up to 80%, respectively [2,4,5,8-10]. As commented earlier, there are in general few studies about the efficacy of treatments for these conditions. This means that about 1.73 – 5.20 million PD patients may suffer from any kind of autonomic dysfunction and may not be treated. It is therefore of maximal importance to develop and test treatments for autonomic disorders in PD.

5. Current research goals

As commented earlier, there are no approved treatments for autonomic dysfunction features in PD, except may be for the use of BTX in sialorrhea or macrocol in constipation. Therefore, the first research goal is to evaluate drugs showing efficacy for the same indication in other patients groups. Many of them are reviewed in Section 7. Clinical trials should
be designed with the highest quality standards, which in general has not been the case up to now. Recommendations for the conduction of such clinical trials are given in Section 8 of this review. Trials for non-pharmacological measures are also needed. As commented earlier, they represent early treatment measures, but their efficacy has been seldom studied.

Another important research goal is to find new targets and therapeutic agents to be tested. Such targets are reviewed in Section 6.

6. Scientific rationale

In this section, the authors will review the physiopathology of autonomic disorders in PD and will try to identify potential targets for future treatments.

6.1 Orthostatic hypotension

Sympathetic dysfunction is a hallmark of OH in PD. For example, compared with age-matched controls, patients with PD have low baroreflex-cardiovagal gain [46]. Reduced gain is even greater in PD with OH. Therefore, orthostatic increments in norepinephrine release in blood vessels sympathetic terminals are reduced and total circulating norepinephrine levels are also reduced. Deposition of Lewy bodies in locus ceruleus and loss of sympathetic post-ganglionic cells have been implicated. But it has been suggested that reduced baroreflex gain is not the only factor related to OH in PD. Indeed, sympathetic denervation of the heart appears to be an important factor [46].

It can thus be hypothesized that restoring baroreflex gain may be an effective treatment for OH in PD. Manipulating breathing patterns or frequency may increase baroreflex sensitivity at least in healthy or hypertensive individuals [47-49]. But, in the presence of organic lesions of the sympathetic nervous systems, such as those observed in PD, there might be less important than expected. In rats, orexin A injections into the medulla can also increase baroreflex sensitivity [50].

Ghrelin, a neuropeptide originally known for its growth hormone-releasing and orexigenic properties and which exerts important pleiotropic effects on the cardiovascular system, has also been shown to increase baroreflex gain in healthy individuals [51]. Particular combination of known antihypertensives can also sensitize baroreflex, probably following blood pressure reductions [52].

Reduced circulating norepinephrine levels in PD patients with OH reveal decreased production and liberation. Therefore, administration of drugs with adrenergic properties such as α1-adrenergic agonists or α2-adrenergic autoreceptors antagonists may also be effective for hypotension treatment. Midodrine, which is considered as the first-line agent against OH [24], acts by stimulating α1-adrenergic receptors. There is no study addressing the efficacy and safety of this drug in PD. Norepinephrine precursors, such as droxidopa, can be also administered.

6.2 Sialorrhea

In adults, about 1.5 l of saliva are secreted daily by three pairs of major salivary glands [53]. The submandibular glands, the parotid glands and the sublingual glands account for about 95% of the total secretion and the remaining 5% is produced by the minor salivary glands.

Salivary glands are controlled by the autonomic nervous system, and are primarily under parasympathetic cholinergic control [53]. It is generally agreed that an increase in the flow of saliva in response to muscarinic agonists is attributable to activation of muscarinic M1, M3 and M5 receptor subtypes [54]. Glands also receive a variable innervation from sympathetic nerves which release norepinephrine from which tends to evoke greater release of stored proteins, mostly from acinar cells but also ductal cells [55]. There is some ‘cross-talk’ between the calcium and cyclic AMP intracellular pathways coupling autonomic stimulation to secretion and salivary protein secretion is augmented during combined stimulation. Sympathetic stimulation on cells receiving parasympathetic impulses modulates the composition of saliva by increasing exocytosis from salivary cells, induces contraction of myoepithelial cells and regulates glandular blood flow.

Therefore, reducing parasympathetic or sympathetic stimulation will lead to reduced saliva outflow. Similarly, sympathetic norepinephrine inhibition may contribute to such reduction. Nonetheless, these interventions can be regarded as palliatives, as the physiopathology of sialorrhea in PD is related to reduced clearance due to impaired swallowing, and not to increased production [56]. It may seem thus more logical to try to find ways to increase swallowing frequency. Lee Silverman Voice Treatment, which can improve dysarthria and dysphagia [50] may be a good candidate but its efficacy has not been explored in PD.

6.3 Sexual dysfunction

Sexual dysfunction is mainly related to vascular autonomic malfunction [57], thus representing the primary target. Neurophysiologic and pharmacological research has elucidated that dopamine and serotonin have central roles in modulating erection and ejaculation [58]. Therefore, dopaminergic degeneration in PD can contribute to altered sexual behavior. Therefore, drugs enhancing penis vasodilation and/or increasing central dopaminergic tone might be good candidates for the treatment of ED in PD. Among such agents, apomorphine may offer special interest, as it has shown some efficacy for treatment of ED [59]. Action mechanism may be both vasodilation and enhancement of central dopaminergic tone. Regrettably its efficacy in PD has never been explored.

6.4 Urinary dysfunction

The lower urinary tract consists of two major components, the bladder and urethra [60]. The bladder is mainly innervated by parasympathetic pelvic nerve. The urethra is innervated by sympathetic and somatic nerves.

Urinary storage is dependent on the reflex arc of the sacral spinal cord. The storage reflex is thought to be tonically
facilitated by the brain, particularly the pontine storage center. The storage function is thought to be further facilitated by the hypothalamus, cerebellum, basal ganglia (particularly through the direct pathway), frontal cortex and by central cholinergic fibers from Meynert nucleus [60]. Reduced bladder capacity together with detrusor overactivity as well as uninhibited external sphincter relaxation are the hallmarks of urinary incontinence in PD [60]. Therefore, inhibition of detrusor activity may be effective for treating incontinence in PD.

6.5 Constipation
The pathophysiological basis for gastrointestinal dysfunction in PD may involve both peripheral and central mechanisms [2]. Damage of the dorsal motor nucleus of the vagus may be the hallmark of constipation in PD and may precede motor symptoms onset. Nonetheless, α-synuclein deposition has also been demonstrated in the enteric nervous system, where loss of dopaminergic neurons has also been shown. Reduced dopaminergic tone may lead to altered peristaltic reflex [61], thus causing delayed colonic transit and anorectal dysfunction [62]. Therefore, therapies accelerating colonic transit may be effective for constipation treatment in PD.

In some patients, pelvic floor dyssynergia may contribute to constipation [62]. Such cases can be regarded as episodes dystonia, and thus should be treated accordingly.

7. Competitive environment
In this section, the authors will review drugs potentially useful for the treatment of autonomic dysfunction in PD. Full searches were conducted in PubMed, Clinicaltrials.gov and Movement Disorders Society International congress from 2002 up to 2012. The focus was on drugs with insufficiently documented efficacy or for which there are clinical trials either planned or ongoing. Inefficacious or unsafe drugs will be briefly mentioned. Results are summarized in Table 2.

| Drug or intervention | Study type | Efficacy results | Safety results |
|----------------------|------------|------------------|---------------|
| Fludrocortisone and domperidone | DB, CO, RCT | Reduced orthostatism symptoms | No major issues |
| Droxidopa | DB, PC, RCT | No significant effect on signs and symptoms. Reduced fall rate | Supine hypertension |
| Fipamezole | DB, PC, RCT | Fipamezole counteracted levodopa-induced BP fall. A confirmatory RCT in underway | No major issues |
| Partial weight supported treadmill gait training | PC, OL, RCT | Increased baroreflex sensitivity | No major issues |
| Entacapone | UC, OL, CS | OH was less frequent in patients exposed to entacapone | Not explored |
| Tropicamide | DB, PC, RCT | Tropicamide 1 mg reduced buccal saliva levels. A confirmatory RCT is underway | No major issues |
| Clonidine | DB, PC, RCT | Patients on clonidine had to dry their mouth less frequently | Somnolence, dizziness |
| Radiotherapy | OL, UC study | Sialorrhea improved after radiotherapy | Loss of taste, dry mouth |
| Sexual dysfunction | Sildenafil | Improved erectile function | No major issues |
| Urinary dysfunction | Fipamezole | Fipamezole counteracted levodopa-induced BP fall. A confirmatory RCT in underway | No major issues |
| BTX-A | OL, UC study | Increased bladder capacity and reduced incontinence episodes | Post-void residue |
| Behavioral therapy | OL, UC study | Reduced incontinence episodes | No major issues |
| Sialorrhea | DB, PC, RCT | Reduced incontinence episodes | Results are not available |
| Sialorrhea | OL, UC study | Results are not available | Results are not available |
| Fludrocortisone and domperidone | DB, CO, RCT | Reduced orthostatism symptoms | No major issues |
| Droxidopa | DB, PC, RCT | No significant effect on signs and symptoms. Reduced fall rate | Supine hypertension |
| Fipamezole | DB, PC, RCT | Fipamezole counteracted levodopa-induced BP fall. A confirmatory RCT in underway | No major issues |
| Partial weight supported treadmill gait training | PC, OL, RCT | Increased baroreflex sensitivity | No major issues |
| Entacapone | UC, OL, CS | OH was less frequent in patients exposed to entacapone | Not explored |
| Tropicamide | DB, PC, RCT | Tropicamide 1 mg reduced buccal saliva levels. A confirmatory RCT is underway | No major issues |
| Clonidine | DB, PC, RCT | Patients on clonidine had to dry their mouth less frequently | Somnolence, dizziness |
| Radiotherapy | OL, UC study | Sialorrhea improved after radiotherapy | Loss of taste, dry mouth |
| Sexual dysfunction | Sildenafil | Improved erectile function | No major issues |
| Urinary dysfunction | Fipamezole | Fipamezole counteracted levodopa-induced BP fall. A confirmatory RCT in underway | No major issues |
| BTX-A | OL, UC study | Increased bladder capacity and reduced incontinence episodes | Post-void residue |
| Behavioral therapy | OL, UC study | Reduced incontinence episodes | No major issues |
| Sialorrhea | DB, PC, RCT | Reduced incontinence episodes | Results are not available |
| Sialorrhea | OL, UC study | Results are not available | Results are not available |
| Fludrocortisone and domperidone | DB, CO, RCT | Reduced orthostatism symptoms | No major issues |
| Droxidopa | DB, PC, RCT | No significant effect on signs and symptoms. Reduced fall rate | Supine hypertension |
| Fipamezole | DB, PC, RCT | Fipamezole counteracted levodopa-induced BP fall. A confirmatory RCT in underway | No major issues |
| Partial weight supported treadmill gait training | PC, OL, RCT | Increased baroreflex sensitivity | No major issues |
| Entacapone | UC, OL, CS | OH was less frequent in patients exposed to entacapone | Not explored |

Drugs with documented lack of efficacy or with significant safety issues are not included in this table but reviewed in the text.

BP: Blood pressure; BTX: Botulinum toxin; CO: Crossover; CS: Cross-sectional study; DB: Double-blind; OH: Orthostatic hypotension; OL: Open-label; PC: Placebo-controlled; RCT: Randomized clinical trial; UC: Uncontrolled.
or fludrocortisone [63]. Thirteen PD patients with symptomatic orthostatism were randomly assigned to one of two possible treatment sequences (fludrocortisone-domperidone or vice versa) allowing a 1-week washout period in between. COMPASS scores were 9 ± 3 at baseline, 6 ± 3 on fludrocortisone (p < 0.04) and 7 ± 2 on domperidone (p < 0.02). Three patients had to be withdrawn during the first week of treatment (two on domperidone and one on fludrocortisone). Five patients reported adverse events during domperidone treatment (nausea (two cases), chest pain, abdominal pain, palpitations and headache) and six during fludrocortisone (nausea (two cases), chest discomfort, morning headache, lightheadedness and dizziness).

7.1.3 Fipamezole
Fipamezole is an α2-adrenergic receptor antagonist with a moderate affinity for histamine H1 and H3 receptors and the serotonin transporter and low affinity for the norepinephrine and dopamine transporters, the α1-adrenergic 1A and 1B receptors and the 5-HT1A and 5-HT7 receptors [68,69]. Fipamezole (JP-1730) is a potent α2-adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of PD [68]. The acute hemodynamic effects of fipamezole were evaluated in a double-blind placebo-controlled study in 21 PD patients [70]. Blood pressure was evaluated during an acute intravenous levodopa challenge. Continuous levodopa treatment significantly decreased mean blood pressure (p < 0.01). Compared with placebo, fipamezole returned blood pressure to prefusion values in a dose-dependent fashion (p < 0.01). A clinical trial is underway to confirm these results (NCT00758849).

7.1.4 Partial weight supported treadmill gait training
Partial weight supported treadmill gait training is sometimes used in rehabilitation in PD. Its cardiovascular effects have been recently evaluated in a controlled open-label study [71]. Sixty PD patients were randomly assigned to undergo conventional gait training or treadmill gait training or no specific intervention. Results showed that while blood pressure did not vary in any group, baroreflex sensitivity improved 80.4% following treadmill gait and by less than 10% in the other groups.

7.1.5 Entacapone
Circumstantial evidence suggesting that entacapone might be effective for treating OH was found in a cross-sectional study conducted by the authors’ group to evaluate factors related to OH in PD [22]. In that study, 20% of patients on entacapone reported hypotension, compared with 45 and 32% of patients on levodopa or on other antiparkinsonian drugs (p < 0.01). They hypothesized that this effect might be achieved by the blockage of norepinephrine degradation by the catechol-O-methyltransferase (COMT) enzyme.

7.2 Drugs for the treatment of sialorrhea
7.2.1 Tropicamide
Tropicamide is a rapid-onset, short-acting muscarinic receptor antagonist. The efficacy of a slowly dissolving, mucoadhesive intra-oral thin film containing tropicamide (NH004) has been explored in a proof-of-concept randomized, double-blind, placebo-controlled, crossover trial [72]. Nineteen PD patients who complained of sialorrhea received three doses (0.3, 1, 3 mg) of tropicamide and placebo in random order, separated by 7 days. For the last seven patients, saliva volume was measured at baseline and 75 min after treatment. The mean decrease in VAS score from baseline to 120 min were -0.55 ± 0.54, -1.08 ± 0.54, -1.53 ± 0.52 and -0.81 ± 0.51 for placebo and 0.3, 1 and 3 mg for tropicamide, respectively (F = 0.6 p = 0.6, ANOVA). Tropicamide 1 mg resulted in a significant VAS score decrease (95% CI -2.57 to -0.48). Saliva volume was reduced by 27, 33 or 20% after tropicamide 0.3, 1 or 3 mg versus 5% with placebo. No adverse events were detected in any of the treatment sequences.
7.2.2 Clonidine
Clonidine is an imidazolic, selective α2-adrenergic receptors agonist. Serrano-Dueñas conducted a double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of clonidine 0.15 mg/day during 3 months in 32 PD patients [73]. On average, patient had to dry their mouths 9 times per 5 min at baseline without between-groups differences. After 3 months of clonidine treatment, patients had to dry their mouths on average 1.47 times, while patients on placebo showed no difference (p < 0.0001). Adverse events were only observed in the clonidine group: diurnal somnolence (2), dizziness (1) and dry mouth (1).

The efficacy and safety of a combination of clonidine and oxybutinin is being explored in a double-blind, randomized, placebo-controlled four-way crossover study [74]. Preliminary result of the data from the first five completed patients showed a trend in saliva secretion rate inhibition.

Clonidine may cause or aggravate OH, suggesting that this side effect should be specifically evaluated in clinical trials with the drug.

7.2.3 Radiotherapy
The long-term efficacy and safety of radiotherapy to the major salivary glands was explored retrospectively [75]. Twenty-eight patients (78% PD, 11% MSA, 11% other parkinsonism) received a bilateral dose of 12 Gy to the parotid and part of the submandibular glands. Sialorrhea improved significantly at 1-month post-radiotherapy and this effect was maintained for at least 1 year. Most frequent adverse events were loss of taste and a dry mouth, 75% of which were transient.

7.2.4 Other drugs
Efficacy and safety of some muscarinic receptor antagonists have been tested in the past. Ipratropium was found to be ineffective in a double-blind, randomized, placebo-controlled cross-over trial [76]. Conversely, atropine showed a potent antisialorrheic effect, but was associated with delirium and hallucinations in three out of seven studied patients [77].

7.3 Sexual dysfunction

7.3.1 Sildenafil
Hussain et al. conducted a randomized, double-blind, cross-over trial to assess the efficacy and safety of sildenafil in 10 PD patients [78]. Subjects were treated during 10 weeks with flexible doses of sildenafil from 25 to 100 mg on an ‘as-needed’ basis 1 h before initiation of the sexual intercourse or with placebo. Significant improvements in the ability to achieve and maintain an erection were found after sildenafil but not after placebo. One patient reported headache and a flushing after sildenafil.

In a larger double-blind, placebo-controlled study, PD patients were randomized to receive 100 mg sildenafil on demand 1 h before sexual activity (n = 118), or similar regimen of placebo (n = 118) [79]. At the end of the trial, differences between sildenafil and placebo groups were significant for the international index of erectile function score (22.6 ± 4.6 vs 14.8 ± 4.2, p < 0.01). Sildenafil was generally well tolerated.

7.3.2 Other drugs
Significant improvements in international index of erectile function have been observed with pergolide [80], but the drug is considered nowadays a second-line antiparkinsonian therapy as it can induce cardiac valvulopathy.

7.4 Urinary dysfunction

7.4.1 Botulinum toxin-A
The efficacy of intravesical BTX injection for overactive bladder symptoms was explored in an open-label uncontrolled study in 16 PD patients [81]. Patients were injected with 500 i.u. of BTX-A into the detrusor. Initial mean functional bladder capacity for the group was 198.6 ± 33.7 ml, which increased to 319 ± 41.1 ml 3 months after treatment. The initial mean SEAPI (stress, emptying, anatomy, protection, inhibition) Incontinence Quality of Life Assessment questionnaire score was 32 ± 3 and 26 ± 6 at 12 months (p < 0.05). No neurological deterioration, confusion or disorientation was noted. None of the evaluated patients needed intermittent or indwelling catheterization after the procedure.

7.4.2 Behavioral therapy
The intervention consisted in training patients to control their pelvic muscles [82]. Computer-assisted anorectal (or vaginal) dual-channel EMG biofeedback was used to help participants identify pelvic floor muscles and teach them to contract and relax these muscles in isolation while keeping rectus abdominis muscles relaxed. Participants were given guidance regarding fluid management (decrease caffeine, drink six to eight 8-ounce glasses of fluid daily) and education regarding constipation as indicated (increase physical activity, fiber and fluid; over-the-counter agent use if needed).

The feasibility and efficacy of this intervention was tested in an uncontrolled, open-label study in 17 PD patients. The median (interquartile range) weekly frequency of baseline urinary incontinence episodes was 9 (4–11) and following intervention was 1 (0–3), representing an 83.3% reduction (45.5 – 100.0, p < 0.0001). Quality of life scores as measured by the International Consultation on Incontinence Questionnaire for overactive bladder instrument improved from 71.1 ± 23.9 to 54.7 ± 15.4 (p < 0.002).

A randomized, double-blind study including 60 patients is underway to further test the efficacy and safety of the intervention (NCT01520948).

7.4.3 Solifenacin succinate
Solifenacin is a M3 muscarinic receptor antagonist which has shown efficacy for the treatment of overactive bladder in the general population [83]. A randomized, double-blind,
placebo-controlled clinical trial in a reduced number of PD patients testing the efficacy and safety of solifenacin succinate up to 10 mg/day is underway (NCT01018264).

7.4.4 Other drugs
Efficacy and safety of intranasal desmopressin was assessed in five PD patients [84]. Three patients dropped out from the study, one due to hyponatremic confusion and two due to lack of efficacy.

7.5 Constipation
7.5.1 Mosapride
Liu et al. conducted an open-label study to assess the efficacy of mosapride 15 mg/day for the treatment of constipation in PD and MSA [85]. Mosapride is a 5-HT4 agonist and partial 5-HT3 antagonist. Six out of the seven included patients completed the study. Colonic transit time was increased by 30%. One patient manifested epigastric discomfort and thus was removed from the study. No worsening of parkinsonism was observed.

7.5.2 Neurotrophin 3
Recently, neurotrophin 3 has been studied for the treatment of gastrointestinal motility problems in PD. Neurotrophin 3 has been shown to produce diarrhea in healthy subjects [86] and was effective in functional constipation [87], the action mechanism remaining unknown. Pfeiffer conducted a randomized controlled clinical trial in six PD patients [88]. Increments in stool frequency, reductions in the amount of days without bowel movements and reduced colonic transit time were noticed in the neurotrophin 3 group as compared with placebo, although they were not statistically significant. Neurotrophin 3 was generally well tolerated, but three patients did reduce dosage due to abdominal cramps or diarrhea.

7.5.3 Lubiprostone
Ondo et al. evaluated the efficacy and safety of lubiprostone, a chloride channel activator, in a double-blind, randomized, placebo-controlled study in PD [89]. Lubiprostone was titrated up to 48 µg/day. Results showed a marked or very marked clinical global improvement was reported by 16 of 25 (64.0%) subjects receiving drug versus 5 of 27 (18.5%) subjects receiving placebo (p < 0.001). Number of bowel movements per day increased after drug treatment (p < 0.001). Adverse events with drug were mild, most commonly intermittent loose stools, with 12 cases in the lubiprostone group versus 1 in the placebo group.

7.5.4 Probiotics
The effects of milk fermented with the probiotic strain Lactobacillus casei Shirota on constipation in PD was explored in an uncontrolled open-label study in 40 PD patients [90]. After probiotic intake, a statistically significant increase in the number of days per week in which stools were of normal consistency (p < 0.01) were observed. The number of days per week in which patients felt bloated (p < 0.01), experienced abdominal pain (p < 0.01) and sensation of incomplete emptying (p < 0.01) were also reduced.

7.5.5 Biofeedback therapy
This intervention involves retraining of muscles involved in defecation and is especially useful in functional constipation with dyssynergic defecation or rectal hyposensitivity. The clinical effects of this intervention are being explored in an uncontrolled, open-label study in a reduced number of PD patients (NCT00869830).

7.5.6 Other drugs
Efficacy and safety of tegaserod, a 5-HT4 agonist, was studied in a randomized, double-blind, placebo-controlled trial in 15 patients [91]. Overall, there was a non-significant trend for decreased constipation in the group that took tegaserod compared with the group that took placebo. No side effects were reported. Tegaserod has been withdrawn from the market because of cardiovascular safety issues.

8. Potential development issues
There is a paucity of methodologically sound clinical trials for non-motor symptoms in PD [20,21]. Randomized controlled clinical trials, using validated outcome measures on appropriate populations are the gold standard for demonstrating drugs’ safety and efficacy [92]. Phase III studies duration should be at least 3 months, considering that dysautonomia represents a chronic condition. Conversely, proof-of-concept Phase II studies can be of shorter duration. As commented earlier, dysautonomic symptoms can be related to PD or to other factors, frequently including drug treatments. It is essential that such drug treatments are controlled during the trial to avoid confounding effects.

In this section, the authors will give some recommendations about study population, outcome measures, study duration and safety assessment when conducting clinical trials for autonomic dysfunction in PD. A summary can be found in Table 3.

8.1 Orthostatic hypotension
There are many unresolved issues regarding the clinical evaluation of OH. In first place, the extent of the blood pressure fall after orthostatism does not always correlate with the presence of symptoms of orthostatism such as lightheadedness or dizziness [22,93]. Moreover, it is not clear whether blood pressure fall should be evaluated by tilt test or standing test and how long should it last after position change [6,93]. The Malmo Preventive Project, which showed that OH is an independent and significant risk factor for all-cause mortality, was based on the classical definition of orthostatic definition and not on the presence of orthostatism symptoms. It may be thus considered that drugs with the ability to reduce the
Orthostatic blood pressure drop after orthostatism may reduce mortality, irrespective of their effect on symptoms. Therefore, some experts may favor using orthostatic blood pressure fall extent as a primary outcome and presence of orthostatism symptoms, standing time patient’s ability in orthostatic activities of daily living [94] as a secondary variable in PD clinical trials. SCOPA-AUT or COMPosite Autonomic Symptom Scale (COMPASS) scales have been recommended for the evaluation of orthostatic symptoms in PD [95]. Patients are usually selected on the basis of the results of standing test. This test, which consists of the evaluation of blood pressure in the supine position and during 3 min after orthostatism, is easy to administer in routine practice [6]. However, it is a problem to consider treating patients simply on the basis of a fall in blood pressure, and to expose them to potentially troublesome adverse drug reactions if they do not complain of clinical symptoms. Therefore, proof-of-concept trials may use changes in blood pressure as a primary end point, and effects on symptoms as a secondary. On the opposite, in Phase III trials, the effects on clinical symptoms might be preferred as a primary outcome, while the changes in blood pressure might be used as secondary explicative outcomes. Patients should also be required to be either untreated or to remain on stable co-treatments with any drugs that could influence blood pressure values. Patients with other forms of neurogenic hypotension, such as MSA or pure autonomic failure, should be excluded as the mechanisms of OH may differ (e.g., orthosympathetic dysfunction in MSA is believed to be rather central and pre-ganglionic, while it is supposed to be mainly peripheral and post-ganglionic in PD patients).

One common side effect of drugs for OH being supine hypertension [96,97], safety assessment should include careful regular assessment of this condition.

### 8.2 Sialorrhea

Sialorrhea can be measured either by quantification of buccal saliva levels or clinical scales. Among the clinical scales, the DSFS, the Drooling Rating Scale or the Sialorrhea Clinical Scale for PD have been suggested for sialorrhea assessment in PD [98,99]. The modified Teacher’s Drooling Scale (mTDS) has also been used for sialorrhea evaluation in PD [30]. DSFS can be used for the retrospective evaluation of sialorrhea, while mTDS can provide on-the-fly evaluations. For inclusion in clinical trials, patients may be selected on the basis of the sialorrhea item in the UPDRS. Patients with xerostomic drugs such as clozapine or other neuroleptics or with significant oral pathology should be excluded or at least studied separately. Xerostomia can be observed as a side effect of drugs for sialorrhea and represents a risk factor for swallowing dysfunction [100]. Dysphagia is frequent in PD and frequently accompanies sialorrhea [101]. Therefore, drug-induced xerostomia can potentially aggravate dysphagia and should thus be always explored in sialorrhea trials in PD. Additionally, if anticholinergics are explored, then cognitive function should be monitored [102].

### 8.3 Sexual dysfunction

Studies on sexual dysfunction should include sexually active males or females and should have at least one sexual encounter per week [79]. Patients with other sexual disorders, such as premature ejaculation or suffering from vasculogenic, psychogenic or endocrinological causes of sexual dysfunction should be excluded. Outcomes may be evaluated by the International Index of Erectile Function [104], but it should be mentioned that no consensus has been reached on the subject.

### 8.4 Urinary dysfunction

Subjective patient-centered outcomes should be employed in Phase III type clinical trials for urinary dysfunction [105]. Simple Likert scales exploring patients’ feelings or treatment benefits can be used. Diaries exploring the frequency of incontinence episodes during a week may result in more significant data. Other symptoms may also be evaluated by standard questionnaires such as the International Prostate Symptom Score or the Danish Prostate Symptom Score [106,107]. Objective tests may also be used, as primary

| Table 3. Empirical recommendations for clinical trials in autonomic dysfunction in PD. |
|-----------------------------------------------|
| **Indication** | **Study population** | **Primary outcome measures** | **Study duration** | **Safety assessments** |
| OH | PD patients fulfilling international OH criteria | Orthostatic blood pressure fall extent | ≥ 12 weeks | Supine hypertension |
| Sialorrhea | PD patients with UPDRS item 6 ≥ 2 or 3 | DSFS, mTDS | ≥ 12 weeks | Dry mouth, dysphagia |
| Sexual dysfunction | Exclude non-PD ED and mood disorders | International Index of Erectile Function | ≥ 12 weeks | No specific recommendation |
| Urinary dysfunction | Exclude non-PD causes of incontinence | Frequency of incontinence episodes | ≥ 12 weeks | Post-void recommendation |
| Constipation | PD patients fulfilling ROME III criteria | Frequency of bowel movements | ≥ 12 weeks | Diarrhea |

DSFS: Drooling Severity and Frequency Scale; mTDS: Modified Teacher’s Drooling Scale; OH: Orthostatic hypotension; PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale.
outcomes of early development phase or explanatory secondary outcomes of Phase III trials. The pad weighing test consists in weighting protective pads before and after treatment. Less frequent leakage will result in dry pads, weighing less. Study duration should be at least 12 weeks, as a ‘learning’ effect has been found for week diaries, producing pronounced placebo effects.

Drugs intended for use in urinary incontinence may affect bladder emptying. It is therefore important to monitor patients for increases in residual urine or urinary tract infections.

8.5 Constipation
There are no validated scales for constipation in PD [99]. A patient-reported outcome assessment is recommended [108]. The use of ‘adequate relief of abdominal pain and discomfort’ as an end point does not seem adequate in PD as it is not the main symptom. On the other hand, mean number of stools per week, which is also frequently used a primary end point in clinical trials, may be used in PD [108]. To be included patients should comply with the ROME III criteria for functional constipation [108]. Patients with irritable bowel disorders should be excluded, but this diagnosis may be problematic in PD. The trials must be long enough to determine if any response will be sustained and to determine the effects of withdrawal of treatment, probably 12 weeks or more. Loose stools or diarrhea are common adverse events of drugs for constipation and should thus be evaluated in all clinical trials.

9. Conclusion
Autonomic dysfunction is a frequent feature of PD for which there are not many available treatments at the moment. BTX or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. On the other hand, there are many drugs under study for these indications. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of ED, BTX or behavioral therapy for urinary incontinence and lubiprostone or probiotics for constipation.

Autonomic dysfunctions are frequent adverse drug reactions. Therefore, before any treatment is administered, patients’ pharmacological treatment should be revisited. In many cases, non-pharmacological measures are available and should be administered in first place. When pharmacological treatments are administered, safety becomes an important concern, and physicians need to bear in mind that many drugs for dysautonomic troubles may treat one symptom while worsening other at the same time (e.g., muscarinic receptor antagonists may cause or aggravate constipation). Clinical trials employing valid outcome measures, targeting specific populations and of appropriate duration are needed to further evaluate efficacy and safety of drugs for autonomic dysfunction. Moreover, animal models are needed to boost the understanding on the physiopathology of these troubles and to test new drugs.

10. Expert opinion
Although treatment of non-motor symptoms has been recognized as an unmet need [8], there is a paucity of clinical trials for drugs aiming to treat them. Apart from BTX and glycopyrrolate for sialorrhea and macrogol for constipation, there are no recommended treatments based on good evidence for other autonomic disorders. Most of the practice is then mainly based on empirical extrapolations from clinical use in other disorders than PD, with consequent uncertainty regarding safety and efficacy. Notwithstanding, there are many potential targets that could be translated into efficacious molecules for these disorders. Increasing sympathetic tone, vascular norepinephrine bioavailability or baroreflex sensitivity might all be effective for the treatment of OH, including using drugs like fipamezole or droxidopa. Therapies for sialorrhea have been based in reducing saliva production by inhibition of acetylcholine secretion using muscarinic blockade. Muscarinic blockers should not cross the blood–brain barrier in order to avoid memory loss and hallucinations, which precludes the use of atropine. It remains to be assessed if selective targeting at different muscarinic receptor subtypes might reduce the risk of other parasympatholytic adverse effects. On the other hand, therapies aimed at increasing swallowing frequency are pathophysiologically sounder and probably more effective.

Treatment of ED with sildenafil seems attractive in the light of available evidence in other groups of patients. Nonetheless, mood disorders cannot be neglected in PD and their treatment may contribute to ameliorating sexual function. Female sexual dysfunction has been less studied in PD, and thus, its evaluation may be taken as the next immediate step. Non-ergot dopamine agonists may also be effective for this indication.

Detrusor overactivity appears to be a hallmark of incontinence in PD, as it is in other group of patients. Thus, efficacy of anticholinergic drugs can be anticipated. Indeed, BTX has shown some efficacy. Nonetheless, muscarinic antagonists, such as solifenacin, should be used with caution as PD patients are at high risk of experiencing limiting side effects of these drugs, including memory loss and hallucinations.

As delayed colonic transit is a common feature in PD, therapies aiming at accelerating it may be effective. Indeed, macrogol, an osmotic laxative and lubiprostone, an activator of chloride channels, have shown some efficacy. Other prokinetics, such as mosapride, should probably be used with caution, in the light of its potential cardiovascular safety problems, which led to tegaserod withdrawal from the market.
The authors would like to finish this review article by firmly encouraging the conduction of sound clinical trials for autonomic dysfunction in PD. Even if research may begin by less stringent proof-of-concept studies, high quality clinical trials are needed in order to allow firm evidence-based recommendations for practicing physicians.

Bibliography

Papers of special note have been highlighted as either of interest (●) or of considerable interest (★★) to readers.

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
2. Pfeiffer RF. Gastrointestinal, urological, and sexual dysfunction in Parkinson’s disease. Mov Disord 2010;25(Suppl 1):594-7
3. The National Institute for Clinical Excellence (NICE). Parkinson’s disease diagnosis and management in primary and secondary care. Clinical Guide 35. The National Institute for Clinical Excellence (NICE). London: 2006
4. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res 2006;16:46-54
5. Senard JM, Rai S, Lapayre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:584-9
6. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161(1-2):46-8
7. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci 2010;289:74-80
8. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Clin Neurosci 1998;5:136-46
9. Proulx M, de Courval FP, Wiseman MA, et al. Salivary production in Parkinson’s disease. Mov Disord 2005;20:204-7
10. Safarinejad MR, Taghva A, Shekarchi B, et al. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res 2010;22:325-35

★★ Sildenafil for the treatment of ED in PD.

11. Hobson P, Islam W, Roberts S, et al. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson’s disease patients and normal controls. Parkinsonism Relat Disord 2003;10:67-71
12. Moore O, Gurevich T, Korczyn AD, et al. Quality of sexual life in Parkinson’s disease. Parkinsonism Relat Disord 2002;8:243-6
13. Hinnell C, Hurt CS, Landau S, et al. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov Disord 2012;27:236-41
14. Feldstein C, Weder AB. Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens 2012;6:27-39
15. Merello M. Sialorrhoea and drooling in patients with Parkinson’s disease: epidemiology and management. Drugs Aging 2008;25:1007-19
16. Chou KL, Evatt B, Hinton V, et al. Sialorrhoea in Parkinson’s disease: a review. Mov Disord 2007;22:2306-13
17. Bianchi J. Causes and strategies for moisture lesions. Nurs Times 2012;108:20-2
18. Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson’s disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci 2002;5:146-61
19. Ogawa E, Sakakibara R, Kishi M, et al. Constipation triggered the malignant syndrome in Parkinson’s disease. Neurol Sci 2012;33:347-50
20. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-31

★★ Evidence-based review about treatments for non-motor symptoms in PD.

21. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26:542-80

★★ Evidence-based review about treatments for non-motor symptoms in PD.

22. Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 2012;18:501-5
23. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005;30:173-8
24. Maule S, Papotti G, Nao D, et al. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007;7:63-70
25. Thompson P, Wright J, Rajkumar C. Non-pharmacological treatments for orthostatic hypotension. Age Ageing 2011;40:292-3
26. Logan IC, Wiltam MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing 2012;41:587-94
27. Lagalla G, Millevoi M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7

★★ BTX for sialorrhea in PD.

28. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-31

Declaration of interest

MV Rey and A Pavy-Le Traon have no conflict to declare. S Perez-Lloret has consulted for UCB Pharma and Neurohealing Pharmaceuticals. Inc. O Rascol has act as an advisor for most drug companies developing antiparkinsonian medications.
Emerging drugs for autonomic dysfunction in Parkinson’s disease

Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol 2008;8:724-8

41. Pare P, Bridges R, Champion MC, et al. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol 2007;21(Suppl B):3B-22B

42. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44

** Macrogol for constipation in PD.**

43. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19-31

44. von Campenhansen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005;15:473-90

45. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6

46. Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76

47. Bhavanani AB, Madanmohan Sanjay Z. Immediate effect of chandra nadi pranayama (left unilateral forced nostril breathing) on cardiovascular parameters in hypertensive patients. Int J Yoga 2012;5:108-11

48. Lin G, Xiang Q, Fu X, et al. Heart rate variability biofeedback decreases blood pressure in high blood pressure subjects by improving autonomic function and baroreflex. J Altern Complement Med 2011;17:137-42

49. Wang YP, Kuo TB, Lai CT, et al. Effects of breathing frequency on baroreflex effectiveness index and spontaneous baroreflex sensitivity derived by sequence analysis. J Hypertens 2012;30:2151-8

** Effects of controlled breathing on baroreflex sensitivity.**

50. Shahid IZ, Rahman AA, Pilowsky PM. Orexin A in rat rostral ventrolateral medulla is pressor, sympathetic-excitatory, increases barosensitivity and attenuates the somatono-sympathetic reflex. Br J Pharmacol 2012;165:2292-303

51. Krapalis AF, Reiter J, Machleidt F, et al. Ghrelin modulates baroreflex-regulation of sympathetic vasomotor tone in healthy humans. Am J Physiol Regul Integr Comp Physiol 2012;302:R1305-12

52. Shang W, Han P, Yang CB, et al. Synergism of ischemia and anlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats. Acta Pharmacol Sin 2011;32:1109-15

53. Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;70:93-6

54. Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009;60:3-21

55. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci 2007;133:3-18

56. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002;72:31-6

57. Mezo G, Rubino A, Caravona N, et al. Sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2008;14:451-6

58. Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med 2011;8(Suppl 4):310-15

59. Feifer A, Carrier S. Pharmacotherapy for erectile dysfunction. Expert Opin Investig Drugs 2008;17:679-90

60. Sakakibara R, Uchiyama T, Yamamichi T, et al. Bladder and bowel dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008;79:1159-64

61. Sakakibara R, Kishi M, Ogawa E, et al. Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsonism Dis 2011;2011:926055

62. Jost WH. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci 2010;289:69-73

63. Schoffer KL, Henderson RD, O’Malley K, et al. Nonpharmacological treatment, florocorticosterone, and...
70. Bara-Jimenez W, Chase TN.

67. Hauser RA, Isaacson S. Impact of orthostatic hypotension in Parkinson’s disease. Mov Disord 2007;22:1543-9

66. Hauser RA, Gil R, Isaacson S. Efficacy of droxidopa in patients with PD. Available from: http://www.movementdisorders.org/congress/congress11/2011

65. Mathias CJ. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the European experience. Clin Auton Res 2008;18(Suppl 1):19-24

64. Kaufmann H. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the US experience. Clin Auton Res 2008;18(Suppl 1):25-9

63. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008;18(Suppl 1):19-24

62. Hauser RA, Gil R, Isaacson S. Impact of treatment with droxidopa in repeat fallers with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension (NOH 306A). Mov Disord 2012;27(Suppl 1):S423

- Droxidopa may reduce fall frequency in PD (published as an abstract).

61. Savola JM, Hill M, Engstrom M, et al. Fipamezole (IP-1730) is a potent alpha (2) adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov Disord 2003;18:872-83

60. Sorbera LA, Castaner J, Bayes M. Fipamezole hydrochloride. Antiparkinsonian, alpha(2)-adrenoceptor antagonist. Drugs Future 2003;28:14-17

59. Bara-Jimenez W, Chase TN. Hemodynamic effects of fipamezole in advanced Parkinson’s disease. Neurology 2006;66:A214-15

- Effects of fipamezole on levodopa-induced blood pressure fall (published as an abstract).

58. Talakad S, Ganesan M, Gupta PK. Effect of partial weight supported treadmill gait training on cardiovascular dynamics in patients with Parkinson’s disease. Mov Disord 2011;26(Suppl 1):S173

57. Lloret SP, Nano G, Carrossa A, et al. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson’s disease patients. J Neurol Sci 2011;310:248-50

- Tropicamide for sialorrhea in PD.

56. Serrano-Dueñas M. Treatment of sialorrhea in Parkinson’s disease patients with clonidine. Double-blind, comparative study with placebo. Neurologia 2003;18:2-6

- Clonidine for sialorrhea in PD.

55. Chnag CT, Chen P. A phase II, double-blind, randomized, placebo-controlled 4-way crossover study to evaluate the relative efficacy and safety of OC oral solution (oxybutynin and clonidine) for sialorrhea in patients with Parkinson’s disease. Mov Disord 2012;27(Suppl 1):S111

- Clonidine and oxybutynin for sialorrhea in PD.

54. Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with Parkinsonism. Mov Disord 2007;22:2430-5

- Radiotherapy for sialorrhea in PD.

53. Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord 2002;17:1318-20

52. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate in the treatment of parkinsonism. Mov Disord 2000;15:889-92

51. Safarinejad MR, Taghva A, Shekarchi B, et al. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res 2010;22:325-35

50. Pohanka M, Kanovsky P, Bares M, et al. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson’s disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol 2004;11:483-8

49. Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson’s disease.

- Behavioral therapy for urinary incontinence in PD.

48. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24

47. Suchowersky O, Furtado S, Rohu G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 1995;10:337-40

46. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 antagonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680-6

45. Chaudhry V, Giuliani M, Petty BG, et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000;23:189-92

44. Parkman HP, Rao SS, Reynolds JC, et al. Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003;98:1338-47

43. Pfieffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2003;2:107-16

42. Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78:1650-4

- Lubiprostone for constipation in PD.

41. Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 2011;57:117-21

- Probiotics for constipation in PD.

40. Sullivan KL, Staffetti JF, Hauser RA, et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord 2006;21:115-16

39. Grimes DA, Schulz KF. An overview of preventive strategies for sialorrhea in patients with Parkinson’s disease. Lancet 2002;359:57-61
93. Jamnadas-Khoda J, Koshy S, Mathias CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory? Mov Disord 2009;24:1747-51

94. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-8

95. Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-92

96. Mansourati J. Orthostatic hypotension: implications for the treatment of cardiovascular diseases. Presse Med 2012;41(11):1111-15

97. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician 2011;84:527-36

98. Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson’s disease. Mov Disord 2009;24:635-46

99. Perez Lloret S, Piran AG, Rossi M, et al. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson’s disease. Mov Disord 2007;22:107-11

100. Samnieng P, Ueno M, Shinada K, et al. Association of hyposalivation with oral function, nutrition and oral health in community-dwelling elderly Thai. Community Dent Health 2012;29:117-23

101. Perez-Lloret S, Negre-Pages L, Ojero-Senard A, et al. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2012;19:28-37

102. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004;27:1043-57

103. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30

104. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 2000;15:305-8

105. European Medicines Agency. Clinical investigation of medicinal products in the treatment of urinary incontinence. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117971.pdf

106. Winge K, Skau AM, Stimpel H, et al. Prevalence of bladder dysfunction in Parkinson’s disease. Neurourol Urodyn 2006;25:116-22

107. Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45

108. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51

Affiliation
Santiago Perez-Lloret1,2 MD PhD, Maria Verónica Rey1,2 PharmD, Anne Pavy-Le Traon1 MD PhD & Olivier Rascol1 MD PhD
1Author for correspondence
2University of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France
E-mail: splloret@fleni.org.ar
3Catholic University, Clinical Pharmacology & Epidemiology Laboratory, Buenos Aires, Argentina